Core Viewpoint - TianKang Pharmaceutical Co., Ltd. is facing significant challenges in its IPO process on the Beijing Stock Exchange, with concerns raised about declining performance, customer loss, high accounts receivable, and the rationale behind its fundraising projects [1][10]. Financial Performance - From 2022 to 2024, the company's net profit dropped from 204 million to 153 million yuan, with non-recurring net profit declining by 18.36% and 11.20% year-on-year in the last two years [2][11]. - In the first three quarters of 2025, the company reported a revenue of 682 million yuan, a decrease of 20.49%, and a net profit of 106 million yuan, down 42.44% year-on-year [2][11]. - Compared to peers like Reap Bio, Keqian Bio, and PlaiKe, which saw average revenue growth of 1.60% and net profit growth of 49.06%, TianKang's performance is notably poor [2][11]. Customer Dynamics - Sales to major direct customers such as Muyuan, New Hope, and Wens Foodstuffs fell by 72.19%, 35.10%, and 38.33% respectively in the first half of 2025 [4][14]. - The average direct sales price of major products dropped from 17,400 yuan in 2022 to 6,500 yuan in the first half of 2025, indicating weak customer retention and competitive differentiation [4][14]. Business Model Challenges - The company's reliance on government procurement is becoming increasingly problematic, with procurement revenue decreasing from 564 million yuan in 2022 to 268 million yuan in the first half of 2025, reflecting a shrinking market [3][13]. - The product matrix is heavily focused on swine vaccines, lacking diversity to mitigate cyclical risks and capture emerging markets, particularly in poultry vaccines where the company has limited offerings [3][13]. Cost Structure and Profitability - Fixed costs have increased significantly, with depreciation from the Suzhou production base reaching 34.99 million yuan in the first half of 2025, further squeezing profit margins amid declining revenues [5][15]. - Despite a reported 9.76% increase in net profit in the first half of 2025, the underlying profitability of the core business remains weak when excluding non-recurring gains [6][16]. Capacity Utilization and Expansion Plans - The company plans to raise 527 million yuan for capacity expansion projects, despite existing low utilization rates of around 36.02% to 44.44% during the reporting period [7][17]. - The rationale for expansion is based on optimistic market growth expectations and the need for upgraded production lines, but the actual execution of these plans is uncertain due to external factors [8][18]. Overall Assessment - The core issues facing TianKang's IPO include a disconnect between its performance and industry trends, slow business model transformation, a narrow product structure, and questions regarding the necessity and effectiveness of its fundraising projects [9][19].